

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

**(1) APPOINTMENT OF AUDITOR AND
(2) POSSIBLE DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS**

This announcement is made by IVD Medical Holding Limited (the “**Company**”) pursuant to Rule 13.51(4) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2)(a) and 13.51(4) of the Listing Rules.

Reference is made to the Company’s announcement dated 17 February 2025 (the “**Announcement**”) in relation to the resignation of auditor. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Board announces that, with the recommendation from the Audit Committee, it has resolved to appoint Prism Hong Kong Limited (“**Prism**”) as the new auditor of the Company with effect from 20 February 2025, to fill the vacancy following the resignation of Moore HK and to hold office until the conclusion of the next annual general meeting of the Company. The Audit Committee has considered a number of factors, including but not limited to (i) the audit proposal of Prism; (ii) its experience, industry knowledge and technical competence in providing audit work for companies listed on the Stock Exchange; (iii) its independence and objectivity; (iv) its reputable standing in the market; and (v) its resources and capabilities, including the size and structure of the proposed audit team.

The Audit Committee has assessed and considered that Prism is eligible and suitable to act as the auditor of the Company. The Board and the Audit Committee are of the view that the appointment of Prism as the new auditor of the Company is in the interest of the Company and the Shareholders as a whole.

The Board would like to welcome Prism on its appointment as the auditor of the Company.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement in relation to its preliminary results in respect of the financial year ended 31 December 2024 (“FY2024”) not later than three months after the end of its financial year of the Company, i.e. on or before 31 March 2025. Under Rule 13.49(2) of the Listing Rules, the preliminary results shall be based on the Company’s financial statements for FY2024 which shall have been agreed with the Company’s auditor.

The Company anticipates that the necessary procedures for finalising the Company’s audited consolidated financial statements for FY2024 might not be completed by 31 March 2025. In such event, the Company may not be able to publish the annual results for FY2024 (the “**2024 Annual Results**”) on or before 31 March 2025 in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules, respectively. Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules, it must announce its results based on the financial results that have yet to be agreed with the auditor (so far as the information is available). The Company is working closely with its auditors with a view to resolve the outstanding matters and complete the audit of the 2024 Annual Results as soon as practicable. As at the date of this announcement and taking into account the current situation, it is expected that the 2024 Annual Results will be published by 11 April 2025, subject to completion of all audit work as agreed with the auditors.

Save as disclosed above, as at the date of this announcement, the Company does not possess any other inside information which is required to be disclosed under the Listing Rules.

In light of the anticipated delay in the publication of the 2024 Annual Results, it is expected that the Board meeting for the purpose of considering and approving, among others, the 2024 Annual Results will be postponed. The Company will announce the date of the Board meeting in due course.

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer’s securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information. In the event that the Company is unable to publish the 2024 Annual Results on or before 31 March 2025, trading in the shares of the Company on the Stock Exchange may be suspended with effect from 9:00 a.m. on 1 April 2025 until the publication of the announcement in relation to the 2024 Annual Results.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 20 February 2025

As at the date of this announcement, the Company has four executive Directors, namely, Mr. Ho Kuk Sing, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Mr. Law Kim Fai, two non-executive Directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive Directors, namely, Mr. Zhong Renqian, Mr. Leung Ka Sing and Mr. Wong Sze Lok.